WRAP Wrapmail Inc.

Canbiola Finalizes Asset Purchase Agreement with Seven Chakras

Canbiola Finalizes Asset Purchase Agreement with Seven Chakras



Attains Proprietary CBD Formulations

HICKSVILLE, NY, Feb. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. () (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps and concentrate, announced today that its wholly owned subsidiary Pure Health Products (PHP) finalized its asset purchase agreement (APA) with .  

Under the terms of this APA, which was entered into January 31, 2019, Canbiola acquired the rights and title to  proprietary formulas, methods, trade secrets related to the manufacturing of  products containing cannabidiol (CBD). This also includes tradename, domain name, and social media sites and other assets of Seven Chakras including but not limited to raw materials, packaging, equipment, marketing materials, and mailing lists.

 will use their proprietary technology to infuse CBD into various consumer products, tinctures (full spectrum), salves, gels, bath (hemp massage oil) and hemp capsules products.  

“We believe this agreement will further strengthen and enhance Canbiola’s brand, distribution and footprint by integrating this CBD product portfolio with our current products and work towards our mission to be the premier provider of the highest quality Hemp natural products on the market,” said Marco Alfonsi, Chief Executive Officer of Canbiola.

In connection with the transaction, the Company has filed a Current Report on Form 8-K on February 26, 2019 with the SEC, which includes a copy of the Asset Purchase Agreement.

About Canbiola, Inc.

Canbiola, Inc. () is a developer, manufacturer, and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps and concentrate. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states. For more information about Canbiola, Inc., please visit: 

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

Follow Canbiola on:

Twitter @CanbiolaHealth

Instagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbd

Follow us on  and 



Investors and Media:

 

(516) 595-9544


Hayden IR

 

(917) 658-7878
EN
27/02/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Wrapmail Inc.

 PRESS RELEASE

Canbiola Announces First Quarter 2019 Results

Quarterly Revenue Increased 741% and Almost Matching Entire Year 2018; Revenue Maintained Gross Margin of 49%Hicksville, New York--(Newsfile Corp. - May 28, 2019) - Canbiola, Inc. (OTCQB: CANB) ("Canbiola" or the "Company"), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate, announced today operating and financial results for the first quarter ended March 31, 2019. "I am pleased to report our successful progress to begin 2019, as is evident by our first quarter revenue, which alm...

 PRESS RELEASE

Canbiola is Registered and Active in the GSA’s System for Award Mana...

Canbiola is Registered and Active in the GSA’s System for Award Management (SAM) and Department of Defense (DOD) Widens the Availability of its CBD Products HICKSVILLE, NY, March 11, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: ) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate, announced today that it is now registered and active in the U.S. government GSA’s System for Award Management (SAM) and Department of Defe...

 PRESS RELEASE

Canbiola Finalizes Asset Purchase Agreement with Seven Chakras

Canbiola Finalizes Asset Purchase Agreement with Seven Chakras Attains Proprietary CBD Formulations HICKSVILLE, NY, Feb. 27, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. () (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps and concentrate, announced today that its wholly owned subsidiary Pure Health Products (PHP) finalized its asset purchase agreement (APA) with .   Under the terms of this APA, which was entered into January 31, ...

 PRESS RELEASE

Canbiola Deploys Initial 100 sam® Units and Readies Next 100 sam® Un...

Canbiola Deploys Initial 100 sam® Units and Readies Next 100 sam® Units Revolutionary CBD Wellness Solution for Tissue Healing and Chronic Pain is Now in the Hands of 100 Medical Professionals HICKSVILLE, NY, Feb. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (: ) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps and concentrate, announced today that its initial 100 Sustained Acoustic Medicine (“sam®”) units have been deployed and are n...

 PRESS RELEASE

Canbiola Deploys Initial 100 sam(R) Units and Readies Next 100 sam(R) ...

Revolutionary CBD Wellness Solution for Tissue Healing and Chronic Pain is Now in the Hands of 100 Medical ProfessionalsHicksville, New York--(Newsfile Corp. - February 21, 2019) -  Canbiola, Inc. (OTCQB: CANB) ("Canbiola" or the "Company"), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps and concentrate, announced today that its initial 100 Sustained Acoustic Medicine ("sam®") units have been deployed and are now available for medical patient use at select medical professional offices.Th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch